Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Matsuo Y, Nagata Y, Wakabayashi M, Ishikura S, Onishi H, Kokubo M, Karasawa K, Shioyama Y, Onimaru R, Hiraoka M. Impact of pre-treatment C-reactive protein level and skeletal muscle mass on outcomes after stereotactic body radiotherapy for T1N0M0 non-small cell lung cancer: a supplementary analysis of the Japan Clinical Oncology Group study JCOG0403. J Radiat Res 2021;62:901-909. [PMID: 34350956 PMCID: PMC8438483 DOI: 10.1093/jrr/rrab065] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Revised: 06/28/2021] [Indexed: 06/13/2023]

For:	Matsuo Y, Nagata Y, Wakabayashi M, Ishikura S, Onishi H, Kokubo M, Karasawa K, Shioyama Y, Onimaru R, Hiraoka M. Impact of pre-treatment C-reactive protein level and skeletal muscle mass on outcomes after stereotactic body radiotherapy for T1N0M0 non-small cell lung cancer: a supplementary analysis of the Japan Clinical Oncology Group study JCOG0403. J Radiat Res 2021;62:901-909. [PMID: 34350956 PMCID: PMC8438483 DOI: 10.1093/jrr/rrab065] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Revised: 06/28/2021] [Indexed: 06/13/2023]

Number

Cited by Other Article(s)

Mazzella A, Orlandi R, Maiorca S, Uslenghi C, Chiari M, Bertolaccini L, Casiraghi M, Lo Iacono G, Girelli L, Spaggiari L. How General and Inflammatory Status Impacts on the Prognosis of Patients Affected by Lung Cancer: State of the Art. Biomedicines 2024;12:1554. [PMID: 39062127 PMCID: PMC11274951 DOI: 10.3390/biomedicines12071554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2024] [Revised: 06/23/2024] [Accepted: 07/09/2024] [Indexed: 07/28/2024] Open

Affiliation(s)

Antonio Mazzella Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
Riccardo Orlandi Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
Sebastiano Maiorca Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
Clarissa Uslenghi Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
Matteo Chiari Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
Luca Bertolaccini Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
Monica Casiraghi Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
Giorgio Lo Iacono Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
Lara Girelli Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
Lorenzo Spaggiari Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.) Division of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy

Collapse

Aoki S, Ishikawa H, Nakajima M, Yamamoto N, Mori S, Omatsu T, Tada Y, Mizobuchi T, Ikeda S, Yoshino I, Yamada S. Safety and Efficacy of Single-Fraction Carbon-Ion Radiotherapy for Early-Stage Lung Cancer with Interstitial Pneumonia. Cancers (Basel) 2024;16:562. [PMID: 38339314 PMCID: PMC10854500 DOI: 10.3390/cancers16030562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2023] [Revised: 01/16/2024] [Accepted: 01/23/2024] [Indexed: 02/12/2024] Open

Affiliation(s)

Shuri Aoki QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan; (S.A.); (M.N.); (N.Y.); (S.M.); (T.O.); (S.Y.)
Hitoshi Ishikawa QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan; (S.A.); (M.N.); (N.Y.); (S.M.); (T.O.); (S.Y.)
Mio Nakajima QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan; (S.A.); (M.N.); (N.Y.); (S.M.); (T.O.); (S.Y.)
Naoyoshi Yamamoto QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan; (S.A.); (M.N.); (N.Y.); (S.M.); (T.O.); (S.Y.)
Shinichiro Mori QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan; (S.A.); (M.N.); (N.Y.); (S.M.); (T.O.); (S.Y.)
Tokuhiko Omatsu QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan; (S.A.); (M.N.); (N.Y.); (S.M.); (T.O.); (S.Y.)
Yuji Tada Department of Pulmonary Medicine, International University of Health and Welfare, Narita Hospital, Hatakeda 852, Narita 286-8520, Japan;
Teruaki Mizobuchi Department of General Thoracic Surgery, Social Welfare Organization Saiseikai Imperial Gift Foundation, Chibaken Saiseikai Narashino Hospital, 1-8-1 Izumi-Cho, Narashino-shi 275-8580, Japan;
Satoshi Ikeda Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka-higashi, Kanazawa-ku 236-0051, Japan;
Ichiro Yoshino Department of Thoracic Surgery, International University of Health and Welfare, Narita Hospital, Hatakeda 852, Narita 286-8520, Japan;
Shigeru Yamada QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan; (S.A.); (M.N.); (N.Y.); (S.M.); (T.O.); (S.Y.)

Collapse

Catikkas NM, Bahat Z, Oren MM, Bahat G. Older cancer patients receiving radiotherapy: a systematic review for the role of sarcopenia in treatment outcomes. Aging Clin Exp Res 2022;34:1747-1759. [PMID: 35169986 DOI: 10.1007/s40520-022-02085-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2021] [Accepted: 01/23/2022] [Indexed: 12/14/2022]

Abstract

BACKGROUND

Previous studies have evaluated the prognostic effects of sarcopenia in cancer patients receiving various treatments, including chemotherapy and surgery, but few studies have focused on radiotherapy (RT).

AIMS

We aimed to investigate the prevalence of sarcopenia and the relationship between sarcopenia and outcomes in older cancer patients who underwent RT without chemotherapy.

METHODS

A systematic review of the literature was conducted in Pubmed/Medline and Cochrane databases in September 2021. We used the search terms and medical subject heading terms "sarcopenia," "low muscle mass (LMM)," "low muscle strength," "LMM and low muscle strength," "LMM and low muscle strength and low physical performance," and "RT." Outcomes were overall survival (OS), progression-free survival, non-cancer death, cancer death, disease-specific survival, local failure-free survival, distant failure-free survival, and RT-related toxicities.

RESULTS

Among 460 studies, 8 studies were eligible for inclusion. The prevalence of sarcopenia was between 42.8% and 72%. Sarcopenia was not associated with OS or OS at 3 years in seven studies in which it was defined as the presence of LMM, while it was related in one study, in which it was defined as the concomitant presence of LMM and muscle strength/function.

DISCUSSION

There was heterogeneity between the studies because there was diversity in their inclusion criteria, definition and assessment methods used for detection of sarcopenia, considered cutoffs for low muscle mass and strength, cross-sectional locations on imaging to assess muscle mass and included covariates. The discrepancy in the results of the studies may also result from the variations in diagnoses, sample sizes, and treatment modalities. The low number of included studies and a small number of patients in each study limited generalizability.

CONCLUSIONS

Sarcopenia may be a prognostic factor, especially in OS when low muscle strength/function is integrated into its definition. We suggest that clinicians focus on muscle strength/function while considering sarcopenia and its association with cancer and RT-related outcomes.

Collapse